New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|March 19, 2015
The Role of High-Dose IL-2 in RCC
Author(s)Mario Sznol, MD
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
Advertisement
Clinical Pearls
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
- There is still a role for high-dose IL-2 in RCC.
- Anti-PD-1 agents are active, but a different population of patients may respond to high-dose IL-2.
- Both agents are necessary to achieve durable remissions.
- If combinations with anti-PD-1 agents prove to be active, IL-2 may be moved to the second- or third-line.
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5